CD133-CAR-NK92 cells demonstrated targeted killing of CD133-positive ovarian cancer cells, particularly when combined with cisplatin, suggesting a strategy for eliminating ovarian CSCs (165). This evidence concerns the gene PROM1 and ovarian carcinoma.